5 results about "Reactive nitrogen species" patented technology

One aspect according to the present invention relates to: a gold nanozyme including glycol chitosan and gold particles; and a pharmaceutical composition for preventing or treating inflammatory bowel disease, the composition comprising the gold nanozyme. The gold nanozyme and the pharmaceutical composition comprising same according to one aspect of the present invention was found to inhibit the expression of inflammatory factors, inhibit the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) inside cells, and reduce the production of nitric oxide (NO) inside cells. In addition, the gold nanozyme was found to inhibit the secretion of Hight Mobility Group Box 1 (HMGB1) when further including glycyrrhizin. In addition, the gold nanozyme and the composition comprising same were found to enable the recovery of the length, weight, etc., of damaged intestines, and thus can be used in the inflammatory bowel disease prevention and / or treatment industry / market.

This invention discloses a solution for inhibiting keloids and its preparation method. Physiological saline is treated with low-temperature atmospheric pressure plasma (CAP) to become activated saline. The activated saline contains a large amount of reactive oxygen species and reactive nitrogen species. After injection into the body, its active ingredients induce disulfide death in fibroblasts derived from keloids, thereby inhibiting keloid formation. Compared with existing methods for inhibiting keloids, this application has several unique advantages. First, the effect and degree of CAP activation on fibroblast life and death are dose-dependent, allowing for precise control of the effect. Second, the full spectrum of active species generated by CAP can synergistically act on multiple biological targets, reducing the risk of recurrence. Third, CAP is administered through the process of generating an activated solution from a liquid medium, enabling non-invasive or minimally invasive drug delivery and greatly reducing the risk of systemic toxicity. Finally, CAP technology avoids complex biological agent preparation processes, making it simpler to operate and lower in cost. This invention fills the gap in research on low-temperature atmospheric pressure plasma inhibition of keloids.

This invention belongs to the field of nanobiomedicine technology, specifically relating to a mitochondrial-targeting copper-based nanoparticle (Qu@Cu-SS31) and its application in the preparation of drugs for treating myocardial infarction. The nanoparticles consist of quercetin (Que) and copper ions (Cu²⁺). + The nanoparticles, consisting of a self-assembly of the mitochondrial-targeting peptide SS31, exhibit a uniform, near-spherical morphology with an average particle size of 17.2 ± 1.6 nm. These nanoparticles specifically target cardiomyocyte mitochondria, responsively releasing Cu²⁺. + Furthermore, Qu@Cu-SS31 restores cardiomyocyte copper homeostasis by downregulating the copper metabolism negative regulator COMMD1, the copper uptake protein CTR1, and the copper chaperone protein CCS. Based on this, Qu@Cu-SS31 exhibits remarkable SOD-like and CAT-like enzyme activities, efficiently scavenging various reactive oxygen species / reactive nitrogen species and significantly reducing oxidative stress. Simultaneously, it inhibits NLRP3 inflammasome activation and Caspase-1-mediated pyroptosis, regulates the Bcl-2 / Bax balance to inhibit apoptosis, and promotes vascular endothelial growth factor expression and angiogenesis.

This application provides a CA-crosslinked, Isatis indigotica-derived carbon dots-loaded dual-responsive OPU hydrogel, its preparation method, and its applications. The hydrogel is prepared using oxidized pullulan as a backbone and chlorogenic acid as a crosslinking agent; carbon dots derived from Isatis indigotica are loaded into the hydrogel. This hydrogel exhibits excellent injectability and self-healing ability, effectively conforming to irregular wound surfaces. Under the stimulation of the acidic and oxidative microenvironment unique to infected wounds, the hydrogel gradually dissociates, achieving controlled release of Isatis indigotica carbon dots and chlorogenic acid. The Isatis indigotica carbon dots exhibit potent antibacterial activity, while chlorogenic acid synergistically works to efficiently scavenge excess reactive oxygen species and reactive nitrogen species, promoting tissue regeneration and reducing inflammatory responses. In vitro and in vivo experiments have confirmed that this hydrogel possesses excellent biocompatibility, exerting anti-infective, antioxidant, and anti-inflammatory effects in the early stages of healing, and promoting angiogenesis and accelerating wound healing in the later stages.

This invention provides a magnesium alloy, its preparation method, and its applications. The magnesium alloy comprises a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body. A protein carrier is adsorbed on the surface of the peroxide coating, and a NO donor is loaded onto the surface of the protein carrier. The magnesium alloy body can generate hydrogen gas in situ within the acidic tumor microenvironment, downregulating the expression of heat shock proteins in tumor cells, making tumor cells sensitive to temperature, and killing tumor cells under a low-intensity alternating magnetic field. Simultaneously, the peroxide coating stimulates the release of NO from the NO donor in the acidic tumor microenvironment, while the magnesium alloy body promotes the production of heat-activated oxygen substances inside cancer cells, which further react with NO to produce more toxic reactive nitrogen substances, achieving further killing of tumor cells.